The University of Southampton
University of Southampton Institutional Repository

SQ grass sublingual allergy immunotherapy tablet for disease-modifying treatment of grass pollen allergic rhinoconjunctivitis

SQ grass sublingual allergy immunotherapy tablet for disease-modifying treatment of grass pollen allergic rhinoconjunctivitis
SQ grass sublingual allergy immunotherapy tablet for disease-modifying treatment of grass pollen allergic rhinoconjunctivitis
BACKGROUND: Allergy immunotherapy is a treatment option for allergic rhinoconjunctivitis (ARC). It is unique compared with pharmacotherapy in that it modifies the immunologic pathways that elicit an allergic response. The SQ Timothy grass sublingual immunotherapy (SLIT) tablet is approved in North America and throughout Europe for the treatment of adults and children (greater than or equal to 5 years old) with grass pollen-induced ARC.

OBJECTIVE: The clinical evidence for the use of SQ grass SLIT-tablet as a disease-modifying treatment for grass pollen ARC is discussed in this review.

METHODS: The review included the suitability of SQ grass SLIT-tablet for patients with clinically relevant symptoms to multiple Pooideae grass species, single-season efficacy, safety, adherence, coseasonal initiation, and cost-effectiveness. The data from the long-term SQ grass SLIT-tablet clinical trial that evaluated a clinical effect 2 years after a continuous 3-year treatment period were presented in the context of regulatory criteria that define a clinically meaningful effect.

RESULTS: This trial demonstrated that the clinical effect of the SQ grass SLIT-tablet is maintained, which is also supported by the immunologic findings.

CONCLUSION: Therefore, the SQ grass SLIT-tablet has an indication as a disease-modifying therapy in Europe, and a sustained effect is recognized in the United States.
1088-5412
92-104
Dahl, R.
ca31be56-52e7-433a-b60e-25e5aba41f78
Roberts, G.
ea00db4e-84e7-4b39-8273-9b71dbd7e2f3
de Blic, J.
4bcc2551-bad2-4ee1-a9e7-b1541aa36ec9
Canonica, G.W.
b9d303f8-7c7d-4e9f-8b51-a92374d98ea0
Kleine-Tebbe, J.
37b07cf7-30c3-4c64-9429-d302e05bd008
Nolte, H.
680b2bcd-0507-40d4-b17e-27766e417b6c
Lawton, S.
40363bea-7500-48a6-94f0-de7116143c41
Nelson, H.S.
28fa9639-5453-4589-a191-e2c32bb4490a
Dahl, R.
ca31be56-52e7-433a-b60e-25e5aba41f78
Roberts, G.
ea00db4e-84e7-4b39-8273-9b71dbd7e2f3
de Blic, J.
4bcc2551-bad2-4ee1-a9e7-b1541aa36ec9
Canonica, G.W.
b9d303f8-7c7d-4e9f-8b51-a92374d98ea0
Kleine-Tebbe, J.
37b07cf7-30c3-4c64-9429-d302e05bd008
Nolte, H.
680b2bcd-0507-40d4-b17e-27766e417b6c
Lawton, S.
40363bea-7500-48a6-94f0-de7116143c41
Nelson, H.S.
28fa9639-5453-4589-a191-e2c32bb4490a

Dahl, R., Roberts, G., de Blic, J., Canonica, G.W., Kleine-Tebbe, J., Nolte, H., Lawton, S. and Nelson, H.S. (2016) SQ grass sublingual allergy immunotherapy tablet for disease-modifying treatment of grass pollen allergic rhinoconjunctivitis. Allergy and Asthma Proceedings, 37 (2), 92-104. (doi:10.2500/aap.2016.37.3937). (PMID:26802643)

Record type: Article

Abstract

BACKGROUND: Allergy immunotherapy is a treatment option for allergic rhinoconjunctivitis (ARC). It is unique compared with pharmacotherapy in that it modifies the immunologic pathways that elicit an allergic response. The SQ Timothy grass sublingual immunotherapy (SLIT) tablet is approved in North America and throughout Europe for the treatment of adults and children (greater than or equal to 5 years old) with grass pollen-induced ARC.

OBJECTIVE: The clinical evidence for the use of SQ grass SLIT-tablet as a disease-modifying treatment for grass pollen ARC is discussed in this review.

METHODS: The review included the suitability of SQ grass SLIT-tablet for patients with clinically relevant symptoms to multiple Pooideae grass species, single-season efficacy, safety, adherence, coseasonal initiation, and cost-effectiveness. The data from the long-term SQ grass SLIT-tablet clinical trial that evaluated a clinical effect 2 years after a continuous 3-year treatment period were presented in the context of regulatory criteria that define a clinically meaningful effect.

RESULTS: This trial demonstrated that the clinical effect of the SQ grass SLIT-tablet is maintained, which is also supported by the immunologic findings.

CONCLUSION: Therefore, the SQ grass SLIT-tablet has an indication as a disease-modifying therapy in Europe, and a sustained effect is recognized in the United States.

Full text not available from this repository.

More information

e-pub ahead of print date: 21 January 2016
Published date: March 2016
Organisations: Human Development & Health

Identifiers

Local EPrints ID: 388714
URI: http://eprints.soton.ac.uk/id/eprint/388714
ISSN: 1088-5412
PURE UUID: 748eaab4-579f-46fb-988e-e6935e23e2a7
ORCID for G. Roberts: ORCID iD orcid.org/0000-0003-2252-1248

Catalogue record

Date deposited: 02 Mar 2016 12:08
Last modified: 18 Feb 2021 17:04

Export record

Altmetrics

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×